Clinical trials: BCG
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating…
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Trial name
- NCT03091660
- Testing
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine
- Where
- 174 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- SWOG Cancer Research Network
Transitional Carcinoma of Urinary Bladder
Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder
Phase II Trial of concurrent administration of intravesical BCG \& Interferon in the treatment and prevention of recurrence of superficial transitional carcinoma of the urinary bladder.
- Trial name
- NCT00539773
- Testing
- BCG, Interferon
- Volunteers
- 10 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Food Allergy, Atopic Dermatitis
Asthma, a Disease Due to a Lack of Bacterial Infections in Childhood.
The degree of TH1-skewing by mycobacteria is controlles by NRAMP1 gene polymorphisms and related to the degree of inhibition of TH2-mediated disease.
- Conditions
- Food Allergy, Atopic Dermatitis, Asthma, Rhinitis
- Trial name
- NCT00200928
- Testing
- BCG
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- The Netherlands Asthma Foundation
Neuroblastoma, Sarcoma
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells.
- Trial name
- NCT00003023
- Testing
- BCG vaccine, monoclonal antibody A1G4 anti-idiotype vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Tuberculosis
Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults
Randomized, controlled, double blind clinical trial in 2 stages (adult stage, infant stage). The first stage includes 18 HIV uninfected, QFT negative, BCG vaccinated, adult participants, randomized 1:1 to receive BCG Vaccine SSI…
- Trial name
- MTBVAC-Ph1b (NCT02729571)
- Testing
- MTBVAC, BCG
- Where
- South Africa
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Biofabri, S.L
Diabetes Mellitus, Type 1, Diabetes type1
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
The purpose of this study is to investigate if repeat bacillus Calmette-Guérin (BCG) vaccinations can confer a beneficial immune and metabolic effect on pediatric Type 1 diabetes.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes
- Trial name
- NCT05180591
- Testing
- Bacillus Calmette-Guérin, Saline Injection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Massachusetts General Hospital
BCG Vaccination Reaction
Safety and Tuberculin Conversion Following BCG Vaccination
The study is an bridging study, observer-blind, randomized, controlled prospective intervention study. The primary objective is evaluate the safety of BCG Vaccine Vial (Bio Farma).
- Trial name
- NCT05124340
- Testing
- BCG vial vaccine, BCG ampoule vaccine
- Where
- Indonesia
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Tuberculosis, HIV
Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination
Rationale: The Bacille Calmette-Guérin (BCG) vaccine protects children against disseminated tuberculosis (TB) including TB meningitis and miliary TB, but efficacy against pulmonary TB is inconsistent among children and adults.
- Trial name
- MVA(TB)029 (NCT01650389)
- Testing
- MVA85A, Candin, BCG Vaccine SSI
- Where
- 2 sites in South Africa
- Volunteers
- 248 people
- Sponsor
- Mark Hatherill
Healthy
A Study of Comparing Safety and Reactogenicity, of Lyophilized BCG Vaccine IP of Green Signal Bio Pharma Private Limited, India With BCG Vaccine of Serum Institute of India Limited in 120 Healthy Children.
To compare Safety and Reactogenecity of BCG vaccine of Green Signal Biopharma Private Limited India with BCG vaccine of serum institute of India limited (SIIL), India in 120 healthy children.
- Trial name
- NCT01250249
- Testing
- BCG Vaccine IP - Serum Institute of India
- Where
- India
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Green Signal Biopharma Private Limited
Bladder Cancer
Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors
To determine if there is an association between basic fibroblast growth factor,vascular endothelial growth factor, and interleukin levels and a patients response to BCG treatment ( as standard treatment)in the urine of patients…
- Trial name
- NCT00216814
- Where
- Canada
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Death, Infant, Morbidity;Infant
Trial to Compare Two Strains of BCG
The trial will be a two-year outcome assessor-blinded RCT at the maternity ward of hospital Simão Mendes (HNSM) in urban Bissau, Guinea-Bissau to compare BCG-Japan versus BCG-Russia 1:1 in 15,000 infants with respect to…
- Trial name
- STRAIN III (NCT04383925)
- Testing
- BCG-Japan, BCG-Russia
- Where
- Guinea-Bissau
- Volunteers
- 16,390 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Tuberculosis
Clinical Study of BCG Vaccine for Intradermal Injection
The study used a randomized, dose-escalation, blinded, placebo-controlled trial design. In this trial, 160 subjects were enrolled.
- Trial name
- NCT04563273
- Testing
- BCG vaccine 1（0.025mg/0.1ml/person）, BCG vaccine 2 （0.05mg/0.1ml/person）, BCG vaccine 3（0.075mg/0.1ml/person）
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Malaria
Revaccination of Young Children With Bacille Calmette Guerin (BCG) Vaccine
BCG has marked immune stimulatory effects in both animal and human studies and observational studies suggest that BCG is associated with a non-specific reduction in mortality in areas with high infant and child mortality.
- Trial name
- NCT00126217
- Testing
- Bacille Calmette Guerin (BCG)
- Where
- Guinea-Bissau
- Volunteers
- 2,871 people
- Sponsor
- Bandim Health Project
Tuberculosis
Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa
Goal of Serum Institute of India Limited (SIIL) is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against tuberculosis…
- Trial name
- NCT02391415
- Testing
- VPM1002, BCG, VPM1002(Hyg+)
- Where
- 4 sites in South Africa
- Volunteers
- 416 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
BCG Vaccination Reaction, Tuberculosis
A Study of GC3107(BCG Vaccine) in Healthy Infants
The purpose of this study is to investigate the efficacy and safety of GC3107 in healthy infants
- Trial name
- NCT03947138
- Testing
- GC3107, Intradermal BCG SSI inj.
- Where
- 2 sites in South Korea
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Atopy, Asthma
Vitamin A Supplementation at Birth and Atopy in Childhood
INTRODUCTION Eight trials studying the effect of providing neonatal vitamin A supplementation (NVAS) have been reported, and another four are underway to test whether NVAS should become WHO policy.
- Conditions
- Atopy, Asthma, Eczema, Food Allergy
- Trial name
- NCT01779180
- Where
- Guinea-Bissau
- Volunteers
- 2,000 people
- Sponsor
- Bandim Health Project
Bladder Cancer
Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer
Non-muscle-invasive bladder cancer (NMIBC) has a high rate of recurrence (60 to 70%) and progression (20 to 30%) to muscle-invasive bladder cancer (MIBC).
- Trial name
- IMMUN VESSIE (NCT04726735)
- Testing
- Samples of bladder tissue
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Bordeaux
Mortality, Morbidity
Vitamin A With BCG Vaccine
Two studies from Asia have suggested a beneficial effect of vitamin A supplementation given at birth. Hypotheses: Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in…
- Trial name
- NCT00168597
- Testing
- Vitamin A
- Where
- Guinea-Bissau
- Volunteers
- 4,800 people
- Sponsor
- Bandim Health Project
Bladder Cancer
BCG With or Without Mitomycin in Treating Patients With Bladder Cancer
RATIONALE: Biological therapies such as BCG use different ways to stimulate the immune system and stop tumor cells from growing.
- Trial name
- NCT00023842
- Testing
- BCG vaccine, mitomycin C, adjuvant therapy
- Where
- 16 sites in Belgium, Italy and 4 more
- Volunteers
- 97 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Tuberculosis
Randomized Controlled Trial of Percutaneous and Intradermal BCG Vaccination.
An open label, randomized, controlled, equivalency trial to compare the efficacy of the percutaneous route of administration with the intradermal route of administration of Japanese (Tokyo) 172 BCG, in the prevention of…
- Trial name
- NCT00242047
- Testing
- Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).
- Where
- South Africa
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- University of Cape Town